Designing antagonists to anti-apoptotic proteins of Bcl-2 family has become an important strategy in cancer
chemotherapy. Using experimental techniques and computational methods, a few numbers of lead inhibitors to the antiapoptotic
proteins have been reported in the literature and a few of them are under clinical trials. In this review, the lead
inhibitors designed using in silico methodologies are exclusively covered, systematically organized and critically
evaluated. An orchestrated in silico strategy for screening and identifying efficient antagonists to the anti-apoptotic
proteins has also been brought into fore.
Keywords: Apoptosis, Bcl-2 family proteins, Cancer, Drug designing, In silico tools, Neoplasm and Structural Bioinformatics, in silico, oligomeric structure, pro-apoptotic proteins
Rights & PermissionsPrintExport